These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29420369)

  • 1. Efficacy and Toxicity of Fifth-line Nivolumab in a 15-Year-Old Girl With Metastatic Juvenile Renal Cell Carcinoma.
    Akbaraly T; Saguintaah M; Topart D; Sirvent N
    J Pediatr Hematol Oncol; 2018 Apr; 40(3):251-252. PubMed ID: 29420369
    [No Abstract]   [Full Text] [Related]  

  • 2. Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.
    Dizman N; Bergerot P; Bergerot C; Lanman RB; Raymond VM; Banks KC; Jones J; Pal SK
    Eur Urol; 2018 Feb; 73(2):308-310. PubMed ID: 28844598
    [No Abstract]   [Full Text] [Related]  

  • 3. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
    Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
    Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NICE Guidance - Nivolumab for previously treated advanced renal cell carcinoma: © NICE (2017) Nivolumab for previously treated advanced renal cell carcinoma.
    BJU Int; 2018 Sep; 122(3):362-370. PubMed ID: 30187657
    [No Abstract]   [Full Text] [Related]  

  • 5. C-reactive protein can be used to predict the therapeutic effects of nivolumab in patients with metastatic renal cell carcinoma.
    Teishima J; Murata D; Hasegawa Y; Moriyama H; Mita K; Matsubara A
    Int J Urol; 2019 Nov; 26(11):1076-1077. PubMed ID: 31368187
    [No Abstract]   [Full Text] [Related]  

  • 6. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
    Zarrabi K; Wu S
    Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor.
    El Mouallem N; Smith SC; Paul AK
    J Oncol Pract; 2018 Aug; 14(8):511-513. PubMed ID: 29920137
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
    Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
    PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO].
    Rexer H; Steiner T; Grünwald V
    Urologe A; 2017 Apr; 56(4):509-511. PubMed ID: 28251253
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis.
    Hale P; Hahn AW; Rathi N; Pal SK; Haaland B; Agarwal N
    J Geriatr Oncol; 2019 Jan; 10(1):149-154. PubMed ID: 29861146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma].
    Tomizawa M; Nakai Y; Maesaka F; Owari T; Hara R; Miyake M; Inoue T; Anai S; Tanaka N; Fujimoto K
    Hinyokika Kiyo; 2018 Oct; 64(10):397-401. PubMed ID: 30543737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Case of Nivolumab-Induced Isolated Adrenocorticotropic Hormone Deficiency Presenting Dyspnea].
    Ito K; Uchida T; Manabe Y; Miyazaki Y; Itoh H; Mishina M; Okuno H
    Hinyokika Kiyo; 2018 Oct; 64(10):391-395. PubMed ID: 30543736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma].
    Hattahara K; Yamasaki T; Sawada A; Tanigaki K; Endo S; Teramoto Y; Banno H; Fuchigami Y; Suzuki R; Fujiwara M; Hida T; Yoshino T; Kita Y; Goto T; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
    Hinyokika Kiyo; 2019 May; 65(5):157-161. PubMed ID: 31247693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudoprogression: A case of metastatic renal clear cell carcinoma treated with nivolumab.
    Tabei T; Tsuura Y; Kobayashi K
    Pathol Int; 2018 Nov; 68(11):627-629. PubMed ID: 30151940
    [No Abstract]   [Full Text] [Related]  

  • 15. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
    Zahoor H; Barata PC; Jia X; Martin A; Allman KD; Wood LS; Gilligan TD; Grivas P; Ornstein MC; Garcia JA; Rini BI
    J Immunother Cancer; 2018 Oct; 6(1):107. PubMed ID: 30333065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Metastatic Cancer Post Solid Organ Transplantation: A Case Report and Review of the Literature.
    Wong K; Shen J; D'Ambruoso S; Stefanoudakis D; Drakaki A
    Transplant Proc; 2019 Nov; 51(9):3053-3058. PubMed ID: 31627918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison.
    Porta C; Szczylik C; Casciano R; Fu S; Amzal B; Lister J; Karcher H; Meng J; Neumann M; Dinet J
    Crit Rev Oncol Hematol; 2019 Jul; 139():143-148. PubMed ID: 30401604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.
    Yoshida K; Takagi T; Kondo T; Kobayashi H; Iizuka J; Fukuda H; Ishihara H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2019 Jun; 49(6):576-580. PubMed ID: 30924496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer.
    Fujiwara R; Inamura K; Yuasa T; Numao N; Yamamoto S; Masuda H; Kawauchi A; Takeuchi K; Yonese J
    Int J Clin Oncol; 2020 Jan; 25(1):151-157. PubMed ID: 31522314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.
    Wu B; Zhang Q; Sun J
    J Immunother Cancer; 2018 Nov; 6(1):124. PubMed ID: 30458884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.